Neurodegenerative Therapies for Tinnitus: New Hope

Tinnitus, the perception of sound without an external source, affects millions worldwide. A 2024 review by J. L. Liu and Peng Liu proposes that tinnitus is not merely a hearing problem but a neurological one, with roots strikingly similar to neurodegenerative conditions. The authors argue that therapeutic strategies developed for diseases like Alzheimer’s could be repurposed to treat tinnitus.

Tinnitus and Neurodegeneration Share a Common Path

Liu and Liu’s central thesis is that chronic tinnitus involves “maladaptive neuroplasticity.” This means the brain’s auditory and associated emotional networks rewire themselves in harmful, persistent ways after sensory loss or trauma. The review identifies four specific mechanisms this process shares with neurodegeneration.

First is neuroinflammation. In the brain, inflammatory cells and molecules can become overactive, damaging neurons and synapses. This process is well-documented in Parkinson’s disease and is now seen in animal models of tinnitus. Second is glutamate-mediated excitotoxicity. Glutamate is the brain’s main excitatory chemical messenger. In excess, it can overstimulate and kill neurons, a key factor in stroke and amyotrophic lateral sclerosis (ALS). Similar hyperactivity is observed in auditory pathways in tinnitus.

The third link is synaptic dysfunction, where communication between neurons breaks down. Finally, aberrant neural network reorganization occurs, where brain regions like those for hearing, attention, and emotion become hyperconnected and hyperactive, locking in the phantom sound perception. This is conceptually similar to the network disruptions seen in dementia.

Three Promising Therapeutic Strategies from Neurology

By mapping these shared mechanisms, the review outlines specific drug classes that could be borrowed from neurology.

Calming Neuroinflammation

Drugs that suppress chronic brain inflammation are a major focus. In animal studies, compounds like minocycline (an antibiotic with anti-inflammatory properties) and TNF-alpha inhibitors have reduced tinnitus-like behaviors. These drugs aim to quiet the inflammatory “soil” that allows maladaptive plasticity to take root. The approach is directly analogous to investigating anti-inflammatory drugs for Alzheimer’s disease.

Regulating Glutamate Excitotoxicity

Given the role of excessive glutamate, drugs that block its receptors (called NMDA or AMPA receptor antagonists) are logical candidates. Memantine, used for Alzheimer’s, has shown mixed but promising results in some tinnitus clinical trials. Other compounds like caroverine, which has both anti-glutamate and antioxidant effects, have demonstrated efficacy in early human studies. The principle is to protect auditory neurons from chemical overstimulation.

Modulating Neurotrophic Factors

Neurotrophic factors are proteins that support neuron survival and health. In neurodegeneration, boosting factors like Brain-Derived Neurotrophic Factor (BDNF) is a therapeutic goal. In tinnitus, the picture is complex. Some evidence suggests BDNF signaling might initially contribute to the unwanted plasticity. However, other factors, like cerebrolysin, a neuropeptide preparation with neurotrophic activity, have shown potential in improving tinnitus in clinical settings. The key is precise modulation rather than simple boosting.

Evidence Status: From Animal Models to Human Trials

The review methodology involved a systematic examination of preclinical and clinical literature. The findings reveal a clear pattern: strong preclinical proof-of-concept with a significant translational gap.

In animal models, where tinnitus-like behavior is induced by noise or drugs, interventions targeting inflammation, glutamate, and neurotrophins consistently show positive effects. These studies are vital for understanding the biological mechanisms. However, human clinical trials for these repurposed drugs are scarce, small, or show variable results. For example, while memantine has been tested, large-scale, definitive trials are lacking. The authors note that successful translation will require careful patient stratification—identifying which tinnitus subtype is driven by which mechanism—and likely combination therapies.

Practical Implications and Future Directions

For clinicians and patients, this research offers a new way to conceptualize tinnitus. It moves the discussion beyond “masking the sound” and toward potentially modifying the underlying brain dysfunction. It also highlights why tinnitus is often comorbid with conditions like anxiety and hyperacusis, as they may involve overlapping neural networks.

The most immediate implication is for clinical trial design. Future studies should consider measuring biomarkers of inflammation or neural hyperactivation in tinnitus patients to match them with the most appropriate repurposed drug. Furthermore, this framework supports the use of neuromodulation techniques like transcranial magnetic stimulation (TMS), which aim to directly correct aberrant network activity, similar to their use in Parkinson’s disease.

Ultimately, the work by Liu and Liu, published in Frontiers in Aging Neuroscience (DOI: 10.3389/fnagi.2026.1835649), provides a cohesive scientific framework. It argues that by borrowing from the advanced field of neurodegeneration, the path to effective, mechanism-based tinnitus treatments may be significantly shortened.